Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Allergan Confident About Continued Growth, Swats Down Competition Concerns

Feb 09 2017

• By Mandy Jackson

GoldKeyInPuzzle_1200x675

Related Content

J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More

Jan 11 2017

Allergan buys chin fat firm Kythera for $2.1bn

Jun 18 2015

Actavis will become Allergan to emphasize branded pharma focus

Feb 19 2015

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Sep 30 2016

Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition

Dec 21 2016

Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter

Nov 03 2016

Allergan's Price Reform Pledge: Will Others Follow?

Sep 07 2016

Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma

Feb 04 2017

VENUS II Paves Way For Allergan's Ulipristal NDA In Uterine Fibroids

Jan 18 2017

Related Companies

Allergan plc

Additional Topics

Commercial Companies Launches Sales & Earnings BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window